Drug-induced phospholipidosis (PLD) is a phospholipid storage disorder characterized by the accumulation of multi-lamellar bodies (myeloid bodies) in tissues. Many of the drugs that cause phospholipidosis in animals and humans are associated with clinical toxicities (e.g. myopathy, kidney injury, QT prolongation, lung injury, and hepatotoxicity). As a result, the interpretation of phospholipidosis in risk assessment remains uncertain in preclinical and clinical development.

Nextcea identified di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) as a validated marker of phospholipidosis to monitor the onset and time course of tissue phospholipidosis in animal and human studies.

Levels of di-22:6-BMP in Sprague-Dawley rat urine compared to controls

Drug-induced phospholipidosis (PLD) is a phospholipid storage disorder characterized by the accumulation of multi-lamellar bodies (myeloid bodies) in tissues. Many of the drugs that cause phospholipidosis in animals and humans are associated with clinical toxicities (e.g. myopathy, kidney injury, QT prolongation, lung injury, and hepatotoxicity). As a result, the interpretation of phospholipidosis in risk assessment remains uncertain in preclinical and clinical development.

Nextcea identified di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) as a validated marker of phospholipidosis to monitor the onset and time course of tissue phospholipidosis in animal and human studies.

About Nextcea, Inc.

Nextcea, Inc. is a drug development service company dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development. Nextcea integrates cross-species biomarker studies with traditional PK/PD and TK/TD. In-house platforms include HPLC/UPLC coupled to mass spectrometry LC-MS and LC-MS/MS (API-6500s and and TripleTOF 6600).

References:
4. Tengstrand E, Miwa G, and Hsieh F. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opin. Drug Metab. Toxicol. 2010 6(5):555-570.